A number of other equities analysts also recently issued reports on VERU. Zacks Investment Research downgraded Veru from a hold rating to a strong sell rating in a research note on Saturday, January 6th. ValuEngine downgraded Veru from a hold rating to a sell rating in a research note on Tuesday, October 31st.
Shares of Veru (NASDAQ:VERU) opened at $1.47 on Tuesday. Veru has a 12-month low of $0.90 and a 12-month high of $3.00. The company has a market capitalization of $78.22, a PE ratio of -6.39 and a beta of 1.24.
ILLEGAL ACTIVITY WARNING: “Veru (VERU) PT Set at $5.00 by HC Wainwright” was published by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.thestockobserver.com/2018/01/13/veru-veru-pt-set-at-5-00-by-hc-wainwright.html.
Veru Company Profile
Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.